Blood Group Genotyping for Sickle Cell and Thalassaemia
Estimated value
—
Awarded value
—
Suppliers
1
Lots
1
1 awarded
Published
10 Jun 2026
Description
Embedding blood group genotyping into routine practice. The primary objective (benefit) of doing so is to ensure patients with rare blood disorders have a minimise risk of adverse reactions through access to blood group genotyping. Due to delays arising from administrative and operational circumstances, NHS England awarded this contract to commencing 25 June 2025 until 31 March 2026.
Scope
- Reference
- C369873
- Commercial tool
- Standalone contract
Submission & procedure
- Procedure
- Direct award
Award details
Awarded supplier(s), contract period and value as published in the award notice.
Awarded value
—
Award date
—
Contract start
—
Contract end
—
Awarded to
NH